DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of GBP 20.45 billion. The enterprise value is 20.46 billion.

Market Cap	20.45B
Enterprise Value	20.46B

Important Dates

The next estimated earnings date is Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-3.01%
Shares Change (QoQ)	-0.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	387.84M

Valuation Ratios

The trailing PE ratio is 44.43.

PE Ratio	44.43
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	12.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 31.05, with an EV/FCF ratio of 40.61.

EV / Earnings	44.45
EV / Sales	6.57
EV / EBITDA	31.05
EV / EBIT	44.14
EV / FCF	40.61

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 1.23.

Current Ratio	1.47
Quick Ratio	1.23
Debt / Equity	1.23
Debt / EBITDA	3.04
Debt / FCF	4.11
Interest Coverage	31.58

Financial Efficiency

Return on equity (ROE) is 27.63% and return on invested capital (ROIC) is 8.01%.

Return on Equity (ROE)	27.63%
Return on Assets (ROA)	5.88%
Return on Invested Capital (ROIC)	8.01%
Return on Capital Employed (ROCE)	16.89%
Revenue Per Employee	314,287
Profits Per Employee	44,903
Employee Count	10,300
Asset Turnover	0.63
Inventory Turnover	2.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.71% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-47.71%
50-Day Moving Average	80.77
200-Day Moving Average	89.54
Relative Strength Index (RSI)	29.42
Average Volume (20 Days)	4,400

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.96

Income Statement

In the last 12 months, DexCom had revenue of GBP 3.22 billion and earned 460.25 million in profits. Earnings per share was 1.14.

Revenue	3.22B
Gross Profit	1.95B
Operating Income	479.26M
Pretax Income	566.33M
Net Income	460.25M
EBITDA	653.15M
EBIT	479.26M
Earnings Per Share (EPS)	1.14

Full Income Statement

Balance Sheet

The company has 2.06 billion in cash and 2.07 billion in debt, giving a net cash position of -11.50 million.

Cash & Cash Equivalents	2.06B
Total Debt	2.07B
Net Cash	-11.50M
Net Cash Per Share	n/a
Equity (Book Value)	1.68B
Book Value Per Share	4.30
Working Capital	1.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 790.38 million and capital expenditures -286.60 million, giving a free cash flow of 503.78 million.

Operating Cash Flow	790.38M
Capital Expenditures	-286.60M
Free Cash Flow	503.78M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 60.46%, with operating and profit margins of 14.88% and 14.29%.

Gross Margin	60.46%
Operating Margin	14.88%
Pretax Margin	17.58%
Profit Margin	14.29%
EBITDA Margin	20.28%
EBIT Margin	14.88%
FCF Margin	15.64%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.01%
Shareholder Yield	3.01%
Earnings Yield	2.25%
FCF Yield	2.46%

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 6.99.

Altman Z-Score	6.99
Piotroski F-Score	n/a